Working together in cardiovascular prevention: the common mission of the European Heart Journal and the European Journal of Preventive Cardiology

Abstract

Get full access to this article

View all access options for this article.

References

Virchow R. Gesammelte Abhandlungen zur wissenschaftlichen Medizin. Frankfurt: AM Meidinger, 1856. 478, fn.

Virchow

. Erinnerungsblatter. Arch Path Anat Physiol 1852; 4: 541–548.

Anitschkow

Chalatow

. Ueber experimentelle Cholester-insteatose und ihre Bedeutung fuer die Entstehung einiger pathologischer Prozesse. Zentrbl Allg Pathol Pathol Anat 1913; 24: 1–9.

de Langen

. Cholesterol metabolism and racial pathology [in Dutch]. Geneesk Tijdschr Nederl Indië 1916; 56: 1–34.

Kromhout

Menotti

Kesteloot

. Prevention of coronary heart disease by diet and lifestyle: evidence from prospective cross-cultural, cohort, and intervention studies. Circulation 2002; 105: 893–898.

Dawber

Meadors

Moore

National Heart Institute, National Institutes of Health, Public Health Service, Federal Security Agency, Washington, DC, Epidemiological approaches to heart disease: the Framingham study presented at a joint session of the epidemiology, health officers, medical care, and statistics sections of the American Public Health Association, at the seventy-eighth annual meeting in St. Louis, Mo, 1950. Am J Public Health Nations Health 1951; 41: 279–281.

Lerner

Kannel

. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986; 111: 383–390.

Haeusler

. Potential future developments in the field of antihypertensive drugs. Eur Heart J 1987; 8: 135–142.

Mancia

de Backer

Dominiczak

. 2007 guidelines for the management of hypertension. Eur Heart J 2007; 28: 1462–1538.

10.

Redon

Olsen

Cooper

. Stroke mortality and trends from 1990 to 2006 in 39 countries from Europe and Central Asia: implications for control of high blood pressure. Eur Heart J 2011; 32: 1424–1431.

11.

European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al. ESC Committee for Practice Guidelines (CPG) 2008–2010 and 2010–2012 Committees. Eur Heart J 2011; 32: 1769–1818.

12.

Tokgozoglu

Bruckert

. Implementation, target population, compliance and barriers to risk guided therapy. Eur J Prev Cardiol 2012; 19: 37–41.

13.

Joseph

Svartberg

Njølstad

. Change in cardiovascular risk factors in relation to diabetes status: the Tromsø study. Eur J Prev Cardiol 2012; 19: 551–557.

14.

Julian

. Birth and growth of the European Society of Cardiology. Eur Heart J 1980; 1: 5–7.

15.

Lüscher

Gersh

Brugada

on behalf of the new editorial board. The European Heart Journal goes global – the road ahead of the editorial tam 2009–2011. Eur Heart J 2009; 30: 1–5.

16.

Lüscher

Dedecke

Gersh

. Happy Birthday European Heart Journal – in 30 years from Cinderella to center stage. Eur Heart J 2011; 31: 1945–1950.

17.

Lüscher TF, Gersh B, Hindricks G, et al. The European Heart Journal on the move – can scientific publishing be further improved? Eur Heart J 2012 (in press).

18.

Saner

Wood

. EJCPR is flourishing. Eur J Cardiovasc Prev Rehabil 2006; 13: 1–2.

19.

Hamm

Bassand

Agewall

ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.

20.

European Society of Gynecology, Association for European Paediatric Cardiology and German Society for Gender Medicine. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147–3197.

21.

Tendera

Aboyans

Bartelink

M-L

. ESC guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J 2011; 32: 2851–2906.

22.

Poldermans

Bax

Boersma

on behalf of the Task Force for Preoperative Cardiac Risk Assessment and Perioperative Cardiac Management in Non-cardiac Surgery; European Society of Cardiology (ESC). Guidelines for pre-operative cardiac risk assessment and perioperative cardiac management in non-cardiac surgery. Eur Heart J 2009; 30: 2769–2812.

23.

Perk

De Backer

Gohlke

. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635–1701.

24.

Moscoso Costa

Ferreira

Aguiar

. Impact of ESC/ACCF/AHA/WHF universal definition of myocardial infarction on mortality at 10 years. Eur Heart J 2012; 33: 2544–2550.

25.

Vahanian

Alfieri

Andreotti

. Guidelines on management of valvular heart disease. Eur Heart J 2012; 33: 2451–2496.

26.

McMurray

JJV

Adamopoulos

Anker

. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J 2012; 33: 1787–1847.

27.

Steg

James

Atar

ESC Committee for Practice Guidelines (CPG). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). Eur Heart J 2012; 33: 2569–2619.

28.

Camm AJ, Lip GY, De Caterina R, et al.; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012 Aug 24.

29.

De Backer

Ambrosioni

Borch-Johnsen

European Society of Cardiology Committee for Practice Guidelines. European Journal of Cardiovascular Prevention & Rehabilitation European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003; 10: 1–10.

30.

Nallamothu B and Lüscher TF. Moving from impact to influence: measurement and the changing role of medical journals. Eur Heart J 2012 [Epub ahead of print].

31.

Galiè

Hoeper

Humbert

on behalf of the Task Force for Diagnosis and Treatment of Pulmonary Hypertension of European Society of Cardiology (ESC); European Respiratory Society (ERS); International Society of Heart and Lung Transplantation (ISHLT). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2009; 30: 2493–2537.

32.

Moya

Sutton

Ammirati

on behalf of the Task Force for the Diagnosis and Management of Syncope; European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA); Heart Failure Association (HFA); Heart Rhythm Society (HRS). Guidelines for the diagnosis and management of syncope. Eur Heart J 2009; 30: 2631–2671.

33.

Habib

Hoen

Tornos

ESC Committee for Practice Guidelines. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis and the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30: 2369–2413.

34.

Focus issue on prevention. Eur Heart J 2012; 34. Issue 4.

35.

Kromhout

Yasuda

Geleijnse

. Fish oil and omega-3 fatty acids in cardiovascular disease: do they really work? Eur Heart J 2012; 34: 436–444.

36.

Genser

Solbernagel

de Backer

. Nutrition in cardiovascular disease: a systematic review and metanalysis. Eur Heart J 2012; 34: 444–451.

37.

Held

Iqbal

Lear

. Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. Eur Heart J 2012; 34: 452–466.

38.

Healy

Matthews

Dunstan

. Sedentary time and cardio-metabolic biomarkers in US adults: NHANES 2003–2006. Eur Heart J 2011; 32: 590–597.

39.

Corrado

Schmied

Basso

. Risk of sports: do we need a pre-participation screening for competitive and leisure athletes? Eur Heart J 2011; 32: 934–944.

40.

Corrado

Drezner

Basso

. Strategies for the prevention of sudden cardiac death during sports. Eur J Cardiovasc Prev Rehabil 2011; 18: 197–208.

41.

Corrado

Pelliccia

Heidbuchel

Section of Sports Cardiology, European Association of Cardiovascular Prevention and Rehabilitation. Recommendations for interpretation of 12-led electrocardiogram in the athlete. Eur Heart J 2010; 31: 243–259.

42.

Mosterd

Senden

Engelfriet

. Preventing sudden cardiac death in athletes: finding the needle in the haystack or closing the barn door? Eur J Cardiovasc Prev Rehabil 2011; 18: 194–196.

43.

Mahabadi

Massaro

Rosito

. Association of pericardial fat, intrathoracic fat and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J 2009; 30: 850–856.

44.

Klingenberg

Hansson

. Treating inflammation in atherosclerotic cardiovascular disease: emerging therapies. Eur Heart J 2009; 30: 2838–2844.

45.

Braunwald

. Creating controversy where none exists: the important role of C-reactive protein in the CARE, AFCAPS/TexCAPS, PROVE IT, REVERAL, A to Z, JUPITER, HEART PROTECTION and ASCOT trials. Eur Heart J 2012; 33: 430–432.

46.

Sever

Poulter

Chang

. on behalf of the ASCOT Investigators Evaluation of C-reactive protein prior to and on-treatment as a predictor of benefit from atorvastatin: observations from the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2012; 33: 486–494.

47.

Mehta

Azfar

Shin

. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using general practice research database. Eur Heart J 2010; 31: 1000–1006.

48.

Barter

Caulfield

Eriksson

on behalf of the ILLUMINATE investigators. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.

49.

Simic

Hermann

Shaw

. Torcetrapib impairs endothelial function in hypertension. Eur Heart J 2011; 33: 1615–1624.

50.

Vergeer

Bots

van Leuven

. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118: 2515–2522.

51.

Voight

Peloso

Orho-Melander

. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380: 572–580.

52.

Stein

Roth

Rhyne

. Safety and tolarability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial. Eur Heart J 2010; 31: 480–488.

53.

Lüscher

Taddei

Kaski

J-C

. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J 2012; 33: 857–865.

54.

Rubinshtein

Kuvin

Soffler

. Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts cardiovascular events. Eur Heart J 2010; 31: 1142–1148.

55.

Landmesser

von Eckardstein

Kastelein

. Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme. Eur Heart J 2012; 33: 1712–1715.

56.

Chapman

Le Goff

Guerin

. CETP–at the heart of the action of lipid-modulating therapy with statins, niacin and CETP inhibitors. Eur Heart J 2010; 31: 149–164.

57.

Chapman

Ginsberg

Amarenco

European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345–1361.

58.

Gopinath B, Flood VM, Rochtchina E, et al. Serum homocysteine and folate but not vitamin B12 are predictors of CHD mortality in older adults. Eur J Cardiovasc Prev Rehabil 2011 [Epub ahead of print].

59.

Antoniades

Antonopoulos

Tousoulis

. Homocysteine and coronary atherosclerosis. From folate fortification to the recent clinical trials. Eur Heart J 2009; 30: 6–15.

60.

Cappuccio

Cooper

D’Elia

. Sleep duration predicts cardiovascular outcomes: a systematic review and meta-analysis of prospective studies. Eur Heart J 2011; 32: 1484–1492.

61.

Grobbee

. The era of preventive cardiology. Eur J Prev Cardiol 2012; 19: 3–4.

62.

Browne

Grobbee

. Cardiovascular prevention and international health: time for action. Eur J Cardiovasc Prev Rehabil 2011; 18: 547–549.

63.

Dieren

van, Beulens

JWJ

Schouw van der

. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17: 3–8.

64.

Fifth Joint Task Force of the European Society of Cardiology, European Association of Echocardiography, European Association of Percutaneous Cardiovascular Interventions, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur J Prev Cardiol 2012; 19: 585–667.

65.

Vanhees

Geladas

Hansen

. on behalf of the writing group. Eur J Prev Cardiol 2012; 19: 1005–1033.

66.

Jiang

Hong

Ronghui

. Knowledge of secondary prevention guidelines for coronary heart disease: results from a physicians’ survey in China. Eur J Prev Cardiol 2012; 19: 991–998.

67.

Ambrosio

Steinhubl

Gresele

. Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. Eur J Cardiovasc Prev Rehabil 2011; 18: 121–128.

68.

Cavender

Nicholls

Lincoff

. Strategies for the development of new PPAR agonists in diabetes. Eur J Cardiovasc Prev Rehabil 2010; 17(Suppl 1): 32–37.

69.

Zannad

Koenig

. Risk-guided therapy: a first step to personalized medicine. Eur J Prev Cardiol 2012; 19(Suppl 2): 5–6.

70.

Thom S, Field J, Poulter N, et al. Use of a Multidrug Pill In Reducing cardiovascular Events (UMPIRE): rationale and design of a randomised controlled trial of a cardiovascular preventive polypill-based strategy in India and Europe. Eur J Prev Cardiol 2012 [Epub ahead of print].

71.

Kotseva

Wood

De Backer

. EUROASPIRE III: a survey on the life style, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009; 16: 121–137.

72.

Kotseva

Wood

De Backer

. EUROASPIRE III. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 countries. Eur J Cardiovasc Prev Rehabil 2010; 17: 530–540.

73.

Piepoli

Corra

Benzer

. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 1–17.

74.

Neubeck

Redfern

Fernandez

. Telehealth interventions for secondary prevention of coronray heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil 2009; 16: 281–289.

75.

Mezzani

Agostoni

Cohen-Solal

. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2009; 16: 249–267.

76.

Warren

Ekelund

Besson

. Assessment of physical activity – a review of methodologies with reference to epidemiological research: a report by the Exercise Physiology Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010; 17: 127–139.

77.

Metsios

Stavropoulos-Kalinoglou

Panoulas

. Association of physically inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovasc Prev Rehabil 2009; 16: 188–194.

78.

Cooney

Dudina

De Bacquer

. How much HDL cholesterol add to risk estimation? A report from the SCORE investigators. Eur J Cardiovasc Prev Rehabil 2009; 16: 304–314.

79.

Eriksson

Zethelius

Eeg-Olofsson

. Blood lipids in 75,048 type 2 diabetic patients: a population-based survey from the Swedish National diabetes register. Eur J Cardiovasc Prev Rehabil 2011; 18: 97–105.

80.

Van Dieren

Beulens

van der Schouw

. The global burden of diabetes and its complications: an emerging pandemic. Eur J Cardiovasc Prev Rehabil 2010; 17(Suppl 1): S3–S8.

81.

Friis-Moller

Thiebaut

Reiss

. Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil 2010; 17: 491–501.